Digoxin Impact on Heart Failure Patients with Atrial Fibrillation

Area of Science:

• Cardiology
• Pharmacology

Background:

• Digoxin, a cardiac glycoside from Digitalis purpurea, has been a long-standing treatment for heart failure (HF) and atrial fibrillation (AF).
• Its therapeutic effects stem from cardiotonic, neurohormonal, and parasympathomimetic actions on the AV node.

Purpose of the Study:

• To critically evaluate the existing evidence regarding the safety and efficacy of digoxin in patients diagnosed with both heart failure and atrial fibrillation.
• To assess the association between digoxin administration and all-cause mortality risk in this patient population.

Main Methods:

• A comprehensive literature search was conducted using PubMed/MEDLINE and SCOPUS databases.
• The review focused on observational studies, clinical trials, and meta-analyses examining digoxin's effects on mortality and adverse outcomes in patients with AF and HF.

Main Results:

• Evidence on digoxin's safety and efficacy in patients with AF and HF is conflicting.
• While generally advised against in patients without HF due to potential adverse outcomes, its use in patients with both AF and HF warrants caution.

Conclusions:

• The precise impact of digoxin on all-cause mortality and adverse events in patients with AF and HF remains uncertain.
• Further high-quality, low-bias clinical trials are necessary to definitively establish digoxin's role and safety profile in this demographic.